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Available online 27 January 2016Over-expression of mutant copper, zinc superoxide dismutase (SOD) in mice induces ALS and has become the
most widely used model of neurodegeneration. However, no pharmaceutical agent in 20 years has extended
lifespan by more than a few weeks. The Copper-Chaperone-for-SOD (CCS) protein completes the maturation
of SOD by inserting copper, but paradoxically human CCS causes mice co-expressing mutant SOD to die within
twoweeks of birth. Hypothesizing that co-expression of CCS created copper deﬁciency in spinal cord, we treated
these pupswith the PET-imaging agent CuATSM, which is known to deliver copper into the CNS withinminutes.
CuATSM prevented the early mortality of CCSxSOD mice, while markedly increasing Cu, Zn SOD protein in their
ventral spinal cord. Remarkably, continued treatment with CuATSM extended the survival of these mice by an
average of 18 months. When CuATSM treatment was stopped, these mice developed ALS-related symptoms
and diedwithin 3months. Restoring CuATSMtreatment could rescue thesemice after they became symptomatic,
providing a means to start and stop disease progression. All ALS patients also express human CCS, raising the
hope that familial SOD ALS patients could respond to CuATSM treatment similarly to the CCSxSOD mice.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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CCS1. Introduction
Mouse and ratmodels of ALSproduced by the overexpression ofmu-
tant copper, zinc superoxide dismutase (SOD) recapitulate the human
disease with higher ﬁdelity than other models based on more recently
discovered ALS-associated mutations. Mutant SODs also confer a toxic
gain-of-function that leads to motor neuron degeneration in humans,
dogs, zebraﬁsh and Drosophila. The ﬁrst mouse model based on high-
expression SODG93A (Gurney et al., 1994) has now become the most
widely used model for any neurodegenerative disease. The symptomsckman).
isconsin - Madison, Madison,
ect.com).
. This is an open access article underof ALS become obvious in these mice around 100 days of age as the
mice lose weight and their hind limbs atrophy. Recent studies have
established that subtle symptoms start earlier than 30 days (Vinsant
et al., 2013a; Saxena et al., 2009).
However, frustrationwith the SODmodels of ALS has grownbecause
20 years of testing in ALS-mutant SODmice have failed to yield an effec-
tive therapy in mice or man. Few pharmaceutical treatments have been
able to extend life by even 10–15% in the high-expressing SODG93Amice
and no agent has been successfully translated into human treatments.
The Prize4Life.org renewed its offer of $1 million for a therapeutic solu-
tion that extends life by 25% in the high-expressing SODG93A mice. The
goal may seem modest because simply breeding from the standard
B6SJL hybrid of these mice to a homogenous B6 background extends
life by 21% from 130 ± 12 to 157 ± 9 days (Leitner et al., 2009). Yet,
the 25% extension of life has not been achieved reproducibly by any
pharmaceutical approach and the treatment of any SOD-based model
of ALS has proven to be a formidable and elusive challenge.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. CuATSM treatment and survival of SODG93AxCCS mice. The dosing schedule with
CuATSM (30 mg/kg given twice a day) is shown on the top as maroon bars. (A) Kaplan–
Meier plot of ALS-survival probability of SODG93AxCCS mice receiving either no
treatment (black dashed line, n = 15), CuATSM treatment stopped at weaning (blue,
n = 6), treatment stopped at weaning and restarted at symptom onset (dashed gray-
blue, n = 7), and continuous CuATSM treatment (black, n = 17). Censored mice are
shown as black circles or gray-blue diamonds. (B) Weights with standard deviations for
the three treated groups are show using the same symbols as in 1A. Only means are
shown after age 600 days because three or fewer mice survived.
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what processes accelerate the development of motor neuron disease in
SOD mice. The most rapid acceleration of ALS ever described results
when the human Copper-Chaperone-for-SOD (CCS) is co-expressed
with human SOD; low-expressing SODG93A mice co-expressing CCS die
of ALS in 30–50 days, about eight times faster than those without ex-
pression of human CCS (Son et al., 2007).
Understanding why CCS accelerates toxicity of SODG93A in mice is
important because ALS patients express human CCS in a much higher
ratio to SOD compared to the ratio of mouse CCS to human SODG93A
expressed in transgenic mice (Rothstein et al., 1999). Son and Elliott
(Son et al., 2008) clearly showed that copper-dependent cytochrome c
oxidase activity is greatly reduced in the low-expressing SODG93AxCCS
mice, consistent with an apparent copper deﬁciency within the spinal
cord. Copper distribution in vivo is determined by afﬁnity gradients
with SOD having the strongest afﬁnity for copper (Banci et al., 2010).
Thus, overexpression of CCS has been proposed to impair copper-
import into mitochondria in low-expressing SODG93AxCCS mice (Son
et al., 2007; Son and Elliott, 2014).
Among the most promising therapeutics for ALS is the copper com-
plex CuATSM. It is protective in the low-expressing SODG93A and
SODG37R ALSmouse models, extending life by 15% and 26% respectively
(Soon et al., 2011; McAllum et al., 2013). CuATSM is used as a PET-
imaging agent for hypoxic tumors in humans (Dearling et al., 2002),
has low toxicity, and penetrates the blood–brain barrier of ALS patients
inminutes (Ikawa et al., 2015). The ATSMmoiety is a small hydrophobic
ligandwith a high afﬁnity for copper in the 2+ oxidation state (Dearling
and Packard, 2010). The rationale for the use of CuATSM as a PET scan-
ning agent comes from selective release of copper in hypoxic tissues
that are able to reduce copper to the 1+ oxidation state (Donnelly
et al., 2012). The unusually low reduction potential of CuATSMprevents
copper release in most tissues (Dearling and Packard, 2010), but allows
selective release of copper in cells with damaged mitochondria
(Donnelly et al., 2012).
We have recently shown that CuATSM can deliver copper to SOD in
SODG37R mice (Roberts et al., 2014). Because of its ability to deliver cop-
per safely, we hypothesized that CuATSM could protect ALS transgenic
models expressing human CCS by providing copper to partially folded
intermediates of SOD. The toxic gain-of-function appears to involve par-
tially unfolded intermediates of SOD, which often lack the metal cofac-
tors critical for stabilizing SOD (Kayatekin et al., 2008). To quantify
binding of copper and zinc to SOD, we have developed a mass spectro-
metric method to measure the entire SOD protein directly from ventral
spinal cord of ALS-affected tissues. Thismethod revealed that nearly half
of the SOD protein in the spinal cord of mutant SOD mice was Cu,Zn
SOD, while the remaining half of SOD protein predominately contained
zinc but not copper (Rhoads et al., 2011, 2013). Based upon these obser-
vations, we therefore investigated how CuATSM might modulate cop-
per binding to SOD and affect the survival of transgenic SOD mice co-
expressing CCS.
2. Results
Without CuATSM treatment, pups expressing SODG93A with CCS
were clearly identiﬁable as runts in the litter as early as 4 days. They
lagged littermates in development by several days and died in 8–
13 days (Fig. 1A). Because the early mortality was most likely due to
copper deﬁciency affecting mitochondria during development (Son
et al., 2008), we tested whether CuATSM would rescue the early
death. CuATSM dissolved in DMSO applied dermally to the back of the
pup's neck was found to be absorbed within 10 min, which provided a
simple means to treat young pups. Remarkably, CuATSM-treated pups
could respond within hours with increased mobility. We then tested a
variety of CuATSM-dosing schemes to rescue the pups and found that
the best protection came from ﬁrst treating mothers during pregnancy
and then treating pups starting at 5 days of age with 30 mg/kg/doseCuATSM twice daily. The prenatal CuATSM treatment allowed all treat-
ed pups to grow normally and completely prevented early mortality.
Once a treatment regime for CuATSM was found that was safe and
avoided the early mortality, we organized blinded randomized trials
to compare how CuATSM affected the survival of SODG93A mice with
and without human CCS co-expression.
2.1. CuATSM Treatment of CCSxSODG93A mice
This trial had three treatment arms as shown in the Scheme at the
top of Fig. 1. The ﬁrst arm assessed the efﬁcacy of continuous treatment.
The second arm assessed the effects of stopping CuATSM treatment at
21 days of age when the critical window for copper in perinatal devel-
opment had passed (Penland and Prohaska, 2004; Prohaska and
Brokate, 2002). The third arm assessed whether restoring CuATSM
treatment after symptom development could inhibit further ALS
progression.
2.2. Continuous treatment
Continuous treatment with CuATSM kept 17 of 17 high-expressing
SODG93AxCCS mice alive for past a year (Fig. 1A; p = 1.6e-9 versus the
untreated group using the Cox proportional hazardmodel with the like-
lihood ratio test). The continuously treated mice remained remarkably
active even after a year (Supplemental Video 1), but most developed
motor issues in their hind limbs by 600 days. The continuously treated
mice gained excessive weight during the ﬁrst year, but subsequently
lost weight starting around 300 days (Fig. 1B). The ﬁrst mouse reached
end stage motor neuron symptoms at 366 days while ﬁve others
reached end stage between 530 to 660 days. Seven of the 17 mice
were censored due to unrelated health issues that arose mostly in
their second year of life (Supplemental Table S1).
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milder than in the standard SODG93Amice, with the hind limbs suffering
less atrophy while the forelimbs remained largely unaffected. The mice
exhibited spasticity in their hind limbswith their toes extended. Consid-
erable strength remained in the extensormuscles. Themice lost weight,
but far more gradually than SODG93A mice reaching end stage. The long
survival could not be explained by a loss of SOD gene copy number, be-
cause all mice retained their full SOD copy number as shown by qPCR
(Supplemental Fig. S1) and as described below accumulated substan-
tially more SOD protein in ventral spinal cord than SODG93A mice with-
out CCS.
2.3. Withdrawal of CuATSM
In the second treatment arm, CuATSM treatment was stopped at
21 days. These SODG93AxCCS mice continued to grow normally for 6–8
weeks, but then developed hind limb spasticity between 70–90 days.
All became end stage between 122 to 132 days with motor symptoms
primarily affecting the hind limbs (Fig. 1A; n = 6; p = 1.3e-5 versus
the untreated group). Their survival was similar to that of the standard
SODG93A mice.
2.4. Restarting CuATSM
In the third treatment arm, CuATSM treatment was stopped at
21 days (n = 7; p = 4.3e-6 versus the untreated group) until the
mice exhibited ataxia at approximately 80 days. Twice daily treatments
with 30 mg/kg CuATSMwere then resumed. The mice gradually recov-
ered over the next 2months and gainedweight (Fig. 1B). The severity of
symptoms was reduced, but three of the mice eventually developed
progressive ALS symptoms 120–180 days later and were sacriﬁced at
302–377 days of age. Three others were sacriﬁced due to other issues
unrelated to ALS as marked on Fig. 1A and described in Supplemental
Table S1.
2.5. Protection obtained with related experimental treatments
Additional test groups of SODG93AxCCS mice have been treated with
different dosages of CuATSM, including mice used to test different
dosing methods. Aggregating all of these groups receiving continuous
treatment with CuATSM revealed that 36 of 36 SODG93AxCCS mice
remained healthy well past 180 days. This age is 38% longer than the
average 130-day survival of untreated SODG93A mice. Some of
SODG93AxCCS mice receiving low dosages of CuATSM in pilot experi-
ments became symptomatic between 230–380 days of age. These
mice were examined by immunohistology and exhibited reactive
astrocytosis and nitrotyrosine accumulation in motor neurons
(Fig. 2A-B). They had 50% fewer motor neurons compared to CCS litter-
mates or asymptomaticmice remaining on CuATSM treatment (Fig. 2C).
Intense nitration of the motor neurons was found relative to CCS-
control spinal cord, particularly in the environment of motor neurons
in the symptomatic spinal cord. Withdrawal of CuATSM resulted in in-
creased nitrotyrosine accumulation and a pronounced astrogliosis
when the mice became end stage (Fig. 2D). The hippocampus of
CuATSM-treated mice appeared unaffected even in symptomatic mice
surviving as long as 650 days (Supplemental Fig. S2).
2.6. Rescue of symptomatic low-expressing SODG93AxCCS mice
Co-expression of CCS in low-expressing SODG93A mice decreased
survival to the 20–50 day range as previously reported (Son et al.,
2007). Starting treatment with CuATSM at 24 days of age rescued
low-expressing SODG93AxCCSmice (n=5) from the early death initially
described (Son et al., 2007). These mice regained weight, showed im-
proved movement within a week, and continued to survive with mini-
mal residual symptoms. At the time treatment was started, these micehad hind limbweaknesswith impaired coordination andwould typical-
ly succumb if untreated after another week. All 5 mice remained
alive and healthy at 480 days. Untreated litters of low-expressing
SODG93AxCCS mice with similar symptoms became end stage within a
week. Low-expressing SODG93A mice without CCS normally reach end
stage at 240–260 days (Son et al., 2007; Son and Elliott, 2014).
2.7. CuATSM and survival in SODG93A mice without CCS co-expression
Without CCS co-expression, CuATSM still provided substantial pro-
tection to high-expressing SODG93A mice (Fig. 3). Based upon prior re-
sults (McAllum et al., 2013) that showed a strong dose-dependence
on survival in SODG37R mice, we chose to use the maximum possible
dosage of CuATSM (100mg/kg/dose) that could be practically delivered
via dermal application in DMSO. This dose is approximately three times
higher than used to treat the CCS co-expressing mice. It was similarly
administered twice daily. When started at 50 days of age, CuATSM ex-
tended the median survival of SODG93A mice by 22 days, a 16% increase
relative to DMSO-treated mice (Fig. 3A; p = 1.6e-5). CuATSM-treated
mice had a median survival of 155 ± 14 days, while the DMSO-
treated control mice had a median survival of 133 ± 12 days.
While the delay of symptom onset and extension of survival were
highly signiﬁcant, CuATSM did not affect the progression of the disease
as measured by development of abnormal gait, by dragging of hind
limbs, or by use of hind limbs for forward propulsion, relative to the
time when mice became end stage (Fig. 3B). Thus, the time of onset
was delayed by CuATSM treatment, but disease progression was unaf-
fected for both early and late-stage symptoms. Nine mice in total were
censored during these studies and are described in Supplemental
Table S2.
When both mothers and SODG93A pups were treated with
100 mg/kg/dose of CuATSM twice daily, the median survival of the
SODG93A mice increased by 25% to 166 ± 14 days compared to the
DMSO-treated group (Fig. 3; p = 3.2e-6). The additional protection
from early treatment was consistent with motor neuron pathology
starting much earlier than commonly thought (Vinsant et al., 2013a;
Saxena et al., 2009; Vinsant et al., 2013b).
2.8. Impact of CuATSM and CCS on Cytochrome c Oxidase Activity
The copper-dependent activity of cytochrome c oxidase in ventral
spinal cordwasnearly equal inmice expressingwild-type SOD,mice ex-
pressing just SODG93A with or without CuATSM treatment, andmice ex-
pressing SODG93AxCCS that were continuously treated with 30mg/kg of
CuATSM (Fig. 4). This measured activity is consistent with previously
reported activities in nontransgenicmice using the same assaymethod-
ology (Prohaska, 1991). When CuATSM was withdrawn from
SODG93AxCCSmice, cytochrome c oxidase activity in spinal cord was re-
duced by 75% when these mice reached end stage around 130 days. In
the SODG93AxCCSmice used for our initial dose-ﬁnding experiments, cy-
tochrome c oxidase activity in spinal cord was highly variable but re-
duced by an average of 30%. These mice received a ﬁfth of the
CuATSM dosage and survived for 280–370 days.
2.9. Impact of CuATSM and CCS on SODG93A protein and metal content
Human SODG93A protein is well-known to be highly expressed in
SODG93A mice based upon activity measurements (Jonsson et al.,
2006). Using mass spectrometry methods that kept copper and zinc-
bound to the SOD protein, we found that nontransgenic mice contained
a total of 3–4 μM of the endogenous mouse Cu,Zn SOD in ventral spinal
cord (all concentrations here refer to themonomer). In contrast, human
SODG93A mice expressed nearly 50 times more human SOD protein
(210 ± 18 μM) when they reached end stage. Approximately 50% of
total SOD was present as mature Cu,Zn SOD, which is the most stable
and enzymatically active form of SOD. Less than 7% was apoSOD that
Fig. 2.Motor neuron death, astrogliosis and tyrosine nitration during the symptomatic phase in CCSxSODG93A mice. All of the mice shown have been treated with CuATSM, which was
necessary to allow the SODG93AxCCS mice to survive the ﬁrst two weeks after birth. (A) Representative images of glial ﬁbrillary acid protein (GFAP red) and choline acetyl transferase
(ChAT blue) in lumbar spinal cord sections from transgenic CCS and symptomatic SODG93AxCCS mice illustrate how reactive astrocytes surround motor neurons during the
symptomatic phase in the SODG93AxCCS mice. In particular, swollen GFAP(+) astrocytes (white arrows) surround choline acetyl transferase-positive (ChAT) motor neurons in the
symptomatic spinal cord (scale bar = 10 μm). (B) Higher expression of nitrotyrosine in the spinal cord is observed during the symptomatic phase in the SODG93AxCCS mice as shown
by a representative image of nitrotyrosine (NO2Tyr — green) costained with ChAT (blue) in lumbar spinal cord sections from transgenic CCS and symptomatic SODG93AxCCS mice.
Scale bar, 10 μm. (C) Representative ChAT staining (blue) in the ventral horn of the spinal cord (the white dotted line demarcates the border between white and gray matter). The bar
graph reports the number of neuronal somas located in Rexed lamina IX (mean ± SEM from 30 slices per group *p b 0.05: scale bar = 50 μm). (D) Withdrawal of CuATSM from
treated SODG93AxCCS increased nitration and astrocytic reactivity. The left panel shows nitrotyrosine (Green) and GFAP (red) in the ventral horn of the spinal cord of a 281 day-old
continuously CuATSM-treated mouse for comparison. The right panel shows that CuATSM withdrawal at weaning signiﬁcant increases tyrosine nitration as well as GFAP expression
that labeled swollen astrocytes that surround motor neurons in the degenerating spinal cord (a white dotted line indicates motor neuron bodies; scale bar = 10 μm).
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copper. This copper-deﬁcient SODwill readily form a heterodimer with
CCS where the copper from CCS is transferred to form Cu,Zn SOD
(Brown et al., 2004; Lamb et al., 2000). However, the slow import of
copper into the CNS apparently limited the maturation of copper-
deﬁcient SOD by CCS to form Cu,Zn SOD in CCSxSODG93A mice.
UsingCuATSM to deliver copper into theCNS,we found that the con-
centration of Cu,Zn SOD increased in SODG93A mice without CCS co-
expression. This increase amounted to 85–90 μM additional Cu,Zn
SODG93A protein accumulating in treated mice (Fig. 5; p = .003 by
ANOVA). This increase was consistent with treated mice surviving
20 days to 60 days longer than untreated mice, allowing more time
for Cu,Zn SOD to accumulate. CuATSM treatment reduced the percent-
age of copper-deﬁcient SOD by 15–21%, but this percentage remained
relatively constant whether the treatment lasted for 1–2 months or for
as long as 5–6months (Fig. 5A). These results suggest that copper load-
ing into SOD in the CNS of SODG93Amice reached a rate-limiting process
that was too slow to keep up with SOD synthesis, which we hypothe-
sized was due to the limited amount of endogenous mouse CCS relative
to human SOD protein.
This hypothesis was tested using SODG93AxCCS mice. With the in-
creased expression of human CCS, CuATSM treatment of these mice re-
sulted in the lowest percentages of copper-deﬁcient SOD that we haveever observed in ventral spinal cord (Fig. 5B). Combined CuATSM treat-
mentwith CCS overexpression also led to a remarkable accumulation of
Cu,Zn SOD,which reached 340±45 μM in the long surviving CCSxSOD-
G93Amice. This is a hundred foldmore SOD protein compared to the en-
dogenousmouse SOD and nearly twice asmuch SOD protein as found in
SODG93A mouse spinal cord without CCS coexpression.
Withdrawal of CuATSMwhen themicewere 21 days of age resulted
in a slight decrease in total SOD comparedwith continuous treatment at
the same age. Withdrawal did not result in subsequent accumulation of
copper-deﬁcient SOD when the mice reached end stage 110 days later.
Thus, CuATSMmay have other actions in addition to copper delivery to
allow SOD to mature to its fully active and stable form.
3. Discussion
The remarkable protection by CuATSM in SODG93AxCCSmice reveals
the complex interplay of copper in survival ofmotor neurons during de-
velopment and in their demise from mutant SOD expression. Without
CCS co-expression, CuATSM is still among the most effective pharma-
ceutical agents in high-expressing SODG93A mice among the hundreds
tested in this model so far (Turner and Talbot, 2008). With CCS co-
expression, CuATSMhelpedmeet the apparent early demand for copper
during development resulting from overexpression of human CCS. In
Fig. 3. Survival probability and symptom onset of SODG93A mice with CuATSM treatment.
(A) Kaplan–Meier survival probabilities of SODG93A mice treated with DMSO starting at
day 50 (solid black, n = 21), CuATSM given twice daily at a dose of 100 mg/kg starting
at day 50 (dashed dot orange, n = 20), or 100 mg/kg starting at day 5 (solid orange,
n = 12). The end stage was determined when the mice could no longer pass the right
test in 15 s. (B) Three stages of disease progression for SODG93A mice plotted relative to
when each mouse reached end stage. CuATSM treatment increased survival by over
3 weeks as shown in panel A by delaying onset rather than affecting progression.
Treatments were DMSO (black, n = 21) or 100 mg/kg CuATSM (red, n = 20) starting at
day 50. The three measures for the onset of symptoms in relative order of severity are
1) an abnormal gait (solid lines), 2) dragging of at least one hind limb (dashed lines),
and 3) failure to use one limb for forward motion (dotted lines).
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SODG93A mice to beyond 600 days while the doubling amount of SOD
protein (Fig. 1). Furthermore, withdrawal of CuATSM initiated motor
neuron disease progression, while restarting treatment arrested further
progression of symptomaticmice for 180–270 days. Thismakes possible
the pharmacological control of disease progression in SOD-transgenic
mice with CuATSM.
Overexpression of human SOD in transgenic mice is known to in-
duce widespread changes in copper homeostasis in the spinal cord
(Tokuda et al., 2013). The basis for these changes likely results from
the large demand created for copper by the accumulation of copper-Fig. 4. Cytochrome c oxidase activity in cerebral cortex from the different treated mouse group
treatedwith ﬁve lower dosages of CuATSM and developed end stage symptoms between 240 an
mice, but fewer samples were available due to use in SOD assays and for immunohistology. Acdeﬁcient, zinc-bound SOD in spinal cord that we have identiﬁed by
mass spectrometry (Roberts et al., 2014; Rhoads et al., 2011, 2013).
The accumulation of copper-deﬁcient SOD is consistent with other re-
ports using indirect assays that show copper depletion from the protein
in multiple ALS-associated mutant SODs in transgenic mice (Jonsson
et al., 2006; Lelie et al., 2011).
The accumulation of copper-deﬁcient, zinc-bound SOD as the pre-
dominant form of misfolded SOD in transgenic mice can be reconciled
with recentﬁndings on the importance of zinc inmodulating the folding
landscape of SOD (Kayatekin et al., 2008). Zinc has been shown to accel-
erate the kinetics of folding of the apoSOD protein by 100-fold, in addi-
tion to stabilizing the SOD monomer thermodynamically by 13 kcal/
monomer (Kayatekin et al., 2008). Because zinc strongly stabilizes un-
folded SOD protein, zinc-containing SOD accumulates in the spinal
cord awaiting copper from CCS to complete its maturation to Cu,Zn
SOD. Copper transport into other organs ismuch faster than into the spi-
nal cord and brain,which is consistentwith the accumulation of copper-
deﬁcient SOD in the CNS (Levenson and Janghorbani, 1994).
There are only about a dozen enzymes in humans that bind copper
(Prohaska, 2014). The vast majority of intracellular copper is bound pri-
marily by two enzymes, cytochrome c oxidase and Cu,Zn SOD. A com-
plex network of copper transporters and chaperones provides the
intracellular delivery of copper to these two enzymes. The net distribu-
tion is driven by the relative afﬁnity gradients for copper (Banci et al.,
2010), with CCS having a stronger afﬁnity for copper than the chaper-
ones for cytochrome c oxidase. The expression of human CCS in the
SODG93AxCCS mice removes the kinetic barrier for loading copper into
zinc-containing SOD. This allows more of the copper in the CNS to be
diverted into SOD, thereby exacerbating the copper deﬁciency created
by SOD overexpression. Withdrawal of CuATSM from SODG93AxCCS
mice resulted in a 75% decrease in cytochrome c oxidase activity when
these mice reached end stage at 130 days (Fig. 4), where as SODG93A
mice reaching end stage at about the same age had no apparent de-
crease in cytochrome c oxidase activity. These data support the role of
human CCS overexpression in increasing delivery of copper to SOD at
the expense of depleting copper from mitochondrial cytochrome c oxi-
dase (Son et al., 2007, 2008).
Mitochondria in the spinal cord are well-known to be a target in
motor neuron diseases (Kong and Xu, 1998) and both CCS and SOD
enter as metal-deﬁcient forms in the mitochondrial intermembrane
space in SOD-transgenic mice (Igoudjil et al., 2011; Manfredi and Xu,
2005; Mattiazzi et al., 2002; Deng et al., 2006; Jaarsma et al., 2001).
This mitochondrial-localized fraction of SOD with CCS should be partic-
ularly effective at competing with cytochrome c oxidase for copper and
potentially can contribute to the accelerated death of SODG93AxCCSs shown in Figs. 1 and 3. The Low Dose group was from pilot studies where the mice were
d 370 days. Similar cytochrome c oxidase activities were observed in spinal cords of these
tivities are reported as the mean ± STD (n = 3).
Fig. 5.Effect of CuATSM treatment onmetal content of SOD. Concentration of apoSOD (gray), Zn-containing, Cu-deﬁcient SOD (orange) andCu,Zn SOD (green) are shownas barswith total
SOD concentration as a black line above. The percentages of zinc-containing SOD and Cu,Zn SOD are also reported for each treatment. (A) The effects of CuATSM treatment on SODG93A
mice, when CuATSM was started at 90 days (30 mg/kg/dose, n = 4), 50 days (100 mg/kg/dose, n = 4), or 5 days (100 mg/kg/dose, n = 4) versus a DMSO control (n = 4). (B) Effect
of CCS co-expression on maturation of SOD with CuATSM treatment starting at 5 days old. The ﬁrst group shows SOD concentrations from SODG93AxCCS mice continuously treated
with CuATSM sacriﬁced for biochemical assays at 130 days (n = 2). The middle group reports SOD concentrations for continuous CuATSM-treated SODG93AxCCS mice that are
N200 days old (n = 6). The ﬁnal group shows concentrations from ~130 day-old SODG93AxCCS mice that were taken off CuATSM at 21 days (n = 5).
6 J.R. Williams et al. / Neurobiology of Disease 89 (2016) 1–9mice. The time course for the early death in our double transgenic mice
is similar to that observed in pregnant mice that have been given
copper-deﬁcient diets in late pregnancy (Prohaska and Brokate, 2002),
and in rat pupsmade copper-deﬁcient prenatally; these pups also suffer
from life-long motor deﬁcits (Penland and Prohaska, 2004). These re-
sults are consistentwith the need to treat high-expressing SODG93AxCCS
mice earlywith CuATSM to avoid the consequences of severe copper de-
ﬁciency during perinatal development.
An eight-fold increase of endogenous mouse CCS expression is one
of the major changes observed in copper homeostasis resulting from
SOD overexpression (Tokuda et al., 2013). In non-transgenic cells, ap-
proximately one CCS molecule is expressed per 7–14 SOD monomers
(Rothstein et al., 1999). In the high-expressing SODG93A mice, there
are 27 genomic DNA copies of human SOD plus the two endogenous
mouse SOD alleles, compared to just two endogenous copies of mouse
CCS. Thus, the eight-fold increase in expression likely represents the
upper limit of endogenous CCS possible, but still too low tomeet the in-
creased demand created by human SOD overexpression. Ourmass spec-
trometry assays in SODG93A mice show that endogenous mouse CCS
cannot catalyze the complete maturation of human SOD in these mice
when treated with CuATSM (Fig. 5). Although human and mouse CCS
share 86% identity (Moore et al., 2000), the efﬁciency of mouse CCS
interacting with human SOD might further limit copper delivery. Thus,
the accumulation of copper-deﬁcient SOD in the CNS may result from
diminished efﬁciency for mouse CCS delivering copper to human SOD,
which is further ampliﬁed by the dramatic difference in expression of
CCS to SOD. Because co-expression of human CCS in the SODG93AxCCS
mice more closely replicates the balance of CCS with SOD found in
humans, familial ALS-SOD patients could potentially respond to
CuATSM treatment more like SODG93AxCCS mice than the standard
SODG93A model.
Familial ALS caused by SODmutations represent only 2–7% of all ALS
cases (Andersen et al., 2003), but there is growing evidence that wild-
type SOD can participate in sporadic ALS (Guareschi et al., 2012; Bosco
et al., 2010; Rakhit et al., 2002). CuATSMmight also have additional pro-
tective actions, such as restoringmitochondrial function. CuATSM is also
known to reduce cytosolic accumulation of TDP43 both in vitro (Parker
et al., 2012) and in vivo (Soon et al., 2011). A broader potential role for
CuATSM beyond ALS is suggested by its efﬁcacy in treating four mouse
models of Parkinson's disease that are unrelated to mutant SOD (Hung
et al., 2012). In addition to supplying copper, CuATSM is also a scavengerof peroxynitrite in thesemodels (Hung et al., 2012) and thismode of ac-
tion is consistent with a role in ALS as well (Estevez et al., 1999; Cassina
et al., 2002; Franco et al., 2013). Tyrosine nitration was reduced in the
SODG93AxCCS mice treated with CuATSM (Fig. 2). Characterization of
these alternative protective actions of CuATSM may help further im-
prove efﬁcacy as well as identify additional mechanisms underlying
the pathogenesis of ALS. Collectively, these studies provide a rationale
for testing CuATSM in sporadic as well as familial SOD patients. Because
CuATSM also rescues symptomatic low-expressing SODG93AxCCS mice
that were never treated as pups, pretreatment of ALS patients may not
necessarily be required for CuATSM to be protective.
Multiple lines of evidence now support the importance of copper as
a pathogenic factor in ALS (Roberts et al., 2014; Jonsson et al., 2006;
Tokuda et al., 2013; Trumbull and Beckman, 2009; Tokuda et al.,
2007). The vulnerability of motor neurons to altered copper homeosta-
sis is highlighted by the discovery that speciﬁc mutations in the copper
transporter ATP7A occur in progressive X-linked spinal muscular atro-
phy type 3 (SMAX3) (Kennerson et al., 2010). A causal linkage is sup-
ported by the targeted knockout in motor neurons of ATP7A in mice,
which results in motor neuron degeneration (Hodgkinson et al., 2015).
Because copper uptake in the CNS is highly regulated and its turn-
over is extremely slow, copper supplements cannot replace CuATSM
for treating ALS. Copper supplements can damage the liver and are gen-
erally toxic at high dosages. CuATSM offers a safe delivery vehicle to by-
pass the distribution systemnaturally limiting copper transport into the
CNS, providing sufﬁcient copper for CCS to complete the maturation of
Cu,Zn SOD while avoiding the toxicity of high dietary copper intake.
4. Materials and methods
4.1. Mouse breeding and husbandry
All mice procedures were conducted in AAALAC approved facilities
following current ethical regulations of the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health (USA)
international guidelines and were approved by Oregon State
University's Institutional Animal Committee. Male SOD-transgenic
mice expressing SODG93A, both the high-expressing SODG93A mice
(B6SJL-Tg(SOD1*G93A)1Gur/J) and low-expressing SODG93A ((B6SJL-
Tg(SOD1*G93A)dl1Gur/J) were obtained from The Jackson Laboratory
(Bar Harbor, ME). These animals were bred against non-transgenic
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generate additional SODG93A transgenic mice. Transgenic mouse line
17 expressing human CCS under control of the PRP promoterwas previ-
ously described (Son et al., 2007). The CCS mice have been maintained
on the same heterozygous background as the SOD mice. Initially,
SODG93AxCCS mice were produced by crossing male SODG93A mice
with hemizygous CCS+/− mice. To maximize the number of double
transgenic mice generated in each litter, we subsequently bred the
CCS mice to homozygosity. Subsequent SODG93AxCCS were generated
by breeding male SODG93A mice against homozygous female CCS mice
to produce litters composed entirely of heterozygous CCS mice. Both
SODG93AxCCS and SODG93A mice had their SOD copy number veriﬁed
by qPCR usingmouse tissue obtained directly from The Jackson Labora-
tory as the reference standard for gene copy number (Fig. S1). The qPCR
protocol for SODwas identical to that described by Appendix A from the
Jackson Laboratory Manual for SODG93A mice (Leitner et al., 2009).
4.2. Study Design
To produce the large numbers of mice needed quickly for therapeu-
tic trials, ﬁve male SODG93A mice were purchased from Jackson
Labs. When the males were within the breeding age for SODG93A mice
(49–75 days of age), eachwasplaced in a cagewith two female breeders
on the same hybrid background purchased from Jackson Laboratories.
After 4–5 days, the males were transferred to new cages containing ad-
ditional female breeders. The pairs of female breeders produced litters
within 1–2 days of each other that were treated as one group for ran-
domization to treatment cages. The pups were genotyped by PCR at
18–20 days of age and weaned at 21 days of age. Mice from these litters
were randomized to pairs of cages containing 3–4 mice per cage and
balanced as closely as possible for coat color. Males were housed sepa-
rately from females and equal numbers of both sexes were enrolled in
the trials. Groups of matched pairs of cages were blindly allocated to
treatment after ﬁlling the cages was completed. Several littermates
that were nontransgenic for SODG93A were also included and evaluated
blindly throughout the study. The SODG93AxCCS mice were produced
similarly by transferringmale hemizygous SODG93Amice into cages con-
taining two homozygous CCS female breeders.
4.3. Statistical Analysis
The survival of SODG93A mice was evaluated by the Cox Proportional
Hazards Model using the likelihood ratio to test statistical signiﬁcance
from SAS 9.4 (PHREG procedure). The Wald statistic commonly used
to calculate signiﬁcance in Cox Proportional Hazards statistical test
fails with the SODG93AxCCS studies because of the large separation of
survival time between groups. Equivalent highly signiﬁcant differences
were obtained with the nonparametric Mantel-Cox (Log-Rank) test
(not shown). Power analyses for the SODG93AxCCS studies showed
that a group size of 1 mouse surviving past 180 days would be highly
signiﬁcant using either the survival of untreated SODG93AxCCS or
SODG93A mice. A minimum group size of six mice was chosen for each
group.
4.4. Treatment Group Assignments and Randomization
The studywas randomized by assigning balanced cages to treatment
groups and the treatment groups were gender-balanced. The assign-
ment of treatment for the paired groups of cages was randomized by a
coin ﬂip by a technician in another laboratory just prior to initiation of
treatment.
4.5. Survival Endpoints and Symptom Assessment for SODG93A mice
The failure of SODG93A mice to right themselves after 30 seconds is
the de facto standard for end-of-life because death invariably followswithin 1–3 days (Scott et al., 2008). These mice have ﬂaccid hind
limbs and have lost signiﬁcant forelimb strength that prevents them
from righting themselves ormoving effectively around the cage. In con-
cordance with discussions with our attending veterinarian and the
IACUC committee, SODG93A mice were deemed to be end stage when
they could no longer right themselves after 15 seconds. The mice were
treated morning and evening and assessed at each treatment time for
the ability to right themselves on both sides. They were given three op-
portunities to do so. In our prior experience, mice that failed to right
themselves in 15 seconds only rarely could right themselves within
30 seconds (Trumbull et al., 2012).
Separate blinded evaluationswere conducted for symptom progres-
sion. Cages were de-identiﬁed by one technician one cage at a time and
presented to a blinded observerworking in a sterile hood for evaluation.
The blinded observer wore red safety goggles to eliminate their ability
to see residual red color from CuATSM on the mouse coat. A random
number generator was used to determine the order of cages to be eval-
uated. Each animal was given a score of 0 to 3 (0—Animals had no obvi-
ous symptoms; 1—Animal has an abnormal gait; 2—Animals dragged
hind limb at least twice in a 12 inch span; 3—Animal is not using limb
for forward motion).
4.6. Assessment of SODG93AxCCS mice
These mice did not experience the same disease progression as
SODG93A mice and we realized that the end stage determination
described for SODG93A mice was inappropriate. The CuATSM-treated
SODG93AxCCS mice generally fail the traditional right test when placed
on a solid surface, butwere still able to right themselves in the cage bed-
ding material, move around the cage, feed themselves and after an ini-
tial weight loss maintained their weight until the last week. Notably,
these mice maintain their forelimb strength. Their difﬁculty in righting
themselves on a solid surface was due to the rigid extension of the
hind limbs that interfered with rolling over when using the front
paws. In the cage, the hind limbs are able to sink into the bedding
allowing the animal to stay upright and use its forelimbs for movement.
In consultation with the head veterinarian and staff, the endpoint was
chosen to be the failure of mice after three attempts to move 15 cm
on a solid surface covered with an absorbent paper towel. Although
the difference in survival assessment added at least 2–4 weeks to the
apparent survival, the end stage SODG93AxCCS mice were still far more
mobile than their SODG93A counterparts.
4.7. Mice censured from trials
All censured mice are described in Supplemental Tables 1 and 2.
There was one major sudden incidence of mortality when 4 CuATSM-
treated mice and 2 DMSO-treated mice at approximately 100 days of
age died from a severe gastrointestinal inﬂammation apparent on au-
topsy. Several mice undergoing DMSO-based treatments independently
of the trials reported here also died unexpectedly at this time. The tox-
icity apparently resulted from a new staff member sterilizing gloves
with Clidox (aqueous chlorine dioxide), whichmay have been absorbed
with DMSO during handling. After switching to 70% ethanol for sterili-
zation of gloves, no deaths have occurred in the following 20 months
using the same CuATSM preparation at the same dose.
4.8. Applying CuATSM treatments
Mice were treated twice daily by applying a 15 μg/μL solution of
CuATSM dissolved in DMSO directly to the skin on the neck and back
of each mouse with a pipette. For larger doses, the CuATSM is applied
in multiple streaks down the back to maximize absorption. Animals
were not shaved as the fur helped to keep the compound on the animal
as theymoved around the cage following treatment. Doseswere adjust-
ed weekly for each cage by weighing all animals and calculating the
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DMSO-treatment group had equivalent volumes of DMSO applied.
Animals were anesthetized with isoﬂuorane, followed by
transcardial perfusionwith heparinized PBS. The spinal columnwas dis-
sected frommicewithout isolating the spinal cord. Tissueswere then ei-
ther ﬁxed for immunohistochemical staining as described below or
frozen in liquid nitrogen. Frozen tissues were stored at −80 °C until
time of use.
4.9. Immunohistochemical staining of mouse spinal cords and brains
Animals were deeply anesthetized and transcardial perfusion was
performed with 0.9% saline and 4% paraformaldehyde in 0.1 M PBS
(pH 7.2–7.4) at a constant ﬂow of 1 mL/min. Fixed spinal cord was re-
moved, post-ﬁxed by immersion in ﬁxative for 24 h, and then trans-
versely sectioned (30–40 μm) on a vibrating microtome (Leica 1000s).
Serial sections were collected in 100 mM PBS for immunohistochemis-
try. Free-ﬂoating sections were permeabilized for 30 min at room
temperature with 0.3% Triton X-100 in PBS, washed with buffered
solutions, blocked with 5% BSA:PBS for 1 h at room temperature,
and incubated overnight at 4 °C in a solution of 0.3% Triton X-100 and
PBS containing the primary antibodies, mouse anti-nitrotyrosine
(1:200, Millipore), rabbit anti-GFAP (1:500, Sigma), or rabbit anti-
ChAT (1:300,Millipore). Nitrotyrosine immunoreactivity was complete-
ly blocked by preincubation of the primary antibody with free
nitrotyrosine (10 mM at pH 7.4). After washing, sections were incubat-
ed in 1:1,000-diluted secondary antibodies conjugated to Alexa Fluor
488 or Alexa Fluor 633. (Invitrogen). Antibodieswere detected by confo-
cal microscopy using a confocal Zeiss LSM 510 META. For Nissl and
myelin staining, the sections were permeabilized for 10 minutes with
PBS+ 0.1% Triton X-100. After washing twice in PBS for 5 min, sections
were incubated with Nissl NeuroTrace (1:200, Invitrogen) and
ﬂuoroMyelin (1:500, Invitrogen) in PBS for 20 min and washing for
10 min in PBS plus 0.1% Triton X–100. The stain was removed and sec-
tions washed 3 times in PBS over 2 h. To examine the brain for possible
changes, 30 brain slices were block for 1 h at room temperature in PBS-
Triton 0.25% - BSA 5%. GFAP antibody (Sigma #G9269, 1:500) was incu-
bated overnight at 4 °C. Nissl staining (Thermo Scientiﬁc, 1:400)was in-
cubated for 30 min at room temperature.
4.10. CuATSM synthesis and formulation
ATSMwas synthesized by adding 4.8 g 4-methyl-3-thiosemicarbazide
to 100mL dry ethanol heated to 60 °C until completely in solution.While
stirring, 2mLof diacetyl (2,3-butadione)was pipetted into the vessel. Ten
drops of concentrated sulfuric acid was added to accelerate the reaction.
ATSM precipitated as an off-white powder that was collected by ﬁltra-
tion. The ATSM precipitate was washed with ethanol and methanol and
then vacuum dried. These reaction conditions were the most commonly
used, but we were successful preparing ATSM using different concentra-
tions and proportions of precursors. All reagents were obtained from TCI
America (Portland, OR).
To incorporate copper, 4 g ATSMwas stirred at room temperature in
100 mL of methanol. The vast majority of the ATSM did not dissolve.
Both ATSM and CuATSM have limited solubility in methanol, but it is
sufﬁcient to facilitate complete copper loading into ATSM. 160 μL of
100 mM copper chloride in water was added drop-wise to the vessel
and the mixture stirred for 30 min. To collect the product, 100 mL of
water was added to completely precipitate CuATSM. CuATSM was col-
lected via ﬁltration and washed with methanol and water on the ﬁlter
prior to vacuum drying. Mass spectrometry conﬁrmed stoichiometric
metal loading into CuATSM. The most common impurity seen was
clusters of CuATSMwith excess copper loading, such as two ATSMmol-
ecules with three bound copper atoms. Excess bound copper was re-
moved by additional washing of the product with methanol and water.To prepare CuATSM for dosing mice, 1.5 g CuATSM was added to a
volumetric ﬂask, brought to volumewith 100mL of dry pharmaceutical
grade DMSO and dissolved in a bath sonicator for 15 min. CuATSM
would not dissolve in DMSO contaminated with water. By using fresh
bottles of dry DMSO andminimizing exposure to moisture, CuATSM so-
lutions were stable in the freezer for manymonths and for over a week
at room temperature.
4.11. SOD Quantitation
High-resolution mass spectrometry (ThermoFinnigan 7 Tesla FT-ICR
Ultra Mass Spectrometer) was performed on homogenized spinal cord
punches as previously described (Roberts et al., 2014; Rhoads et al.,
2011, 2013). Approximately 200 μg of ventral spinal cord tissue was
weighed on a Cahn 25 Automatic Electrobalance (Cerritos, CA, USA)
and homogenized for 30 seconds in 10 mM ammonium acetate buffer
with an adapted microcentrifuge tube pestle. A hole drilled in the
shaft of the pestle allowed for complete sample and buffer recovery by
brieﬂy centrifuging the homogenate while the pestle was suspended
above the sample by a paper clip. After removing the pestle, a superna-
tant was generated by centrifuging the sample for 2 minutes at
13,000 ×g. Aliquots of the supernatant were loaded onto themass spec-
trometer via a C4 ZipTip® (Millipore). Bovine SOD was added to ali-
quots (ﬁnal concentration of 300 nM) as an internal standard for
quantitation. The data were analyzed using a customMatlab™ program
that calculates theoretical isotope distributions of SOD to identify the
different metal bound species (Rhoads et al., 2013).
4.12. Cytochrome c oxidase assays
This activity was determined by following the oxidation of reduced
cytochrome c as decreased absorbance at 550 nm. Reduced cytochrome
c was prepared by incubating horse heart cytochrome c (Sigma) with
ascorbic acid; excess ascorbic acidwas removedusing a centrifugal ﬁlter
unit (3,000MWCO). Tissue punches (~500 μgwetweight)were collect-
ed on dry ice from frozen brain motor cortex and then homogenized
(10 μg/μl) in 50 mM phosphate buffer pH 7 containing 20 μM EDTA
with 24 units/ml catalase and 0.1% Triton X-100 added immediately
prior to the time of enzyme assay. Tissue homogenate was diluted
1:250. Enzyme activity deﬁned as one unit oxidizing 1.0 μmol of
ferrocytochrome c per minute at 25 °C, pH 7.0 per mg wet tissue,
using 21.8 mM-1·cm−1 as the differential extinction coefﬁcient for
horse heart cytochrome c.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2016.01.020.
Acknowledgments
We thank Kristin Clausing, the vivarium staff and Dr. Helen Diggs,
our attending veterinarian for their support and partnership inmonitor-
ing the health of themice and quick identiﬁcation of emerging health is-
sues affecting the mice. We thank Michael Camillo as well as Burgess
and Libby Jamieson for donations to the Linus Pauling Institute that
made this work possible. This work was once funded by AT002034
(JSB), NS058628 (JSB), and NS036761 (AGE) and supported by the
Amyotrophic Lateral Sclerosis Association (16-IIP-320). It is currently
funded by AL140108 from the Department of Defense (JSB). The SOD
analyses were made possible by the Oregon State University Biomolec-
ular Mass Spectrometry Core Facility and the NIEHS ES000210 Core
Center (JSB). The Muscular Dystrophy Association supports JLE. The
Australian National Health and Medical Research Association provided
Project Grant 1061550 (PJC and BRR) and CDF2 1084972 (PJC) from
the Australian government. This publication was made possible in part
by award number 1337774 from the National Science Foundation,
MRI: Acquisition of Confocal and Two-Photon Excitation Microscope
9J.R. Williams et al. / Neurobiology of Disease 89 (2016) 1–9in the Confocal Microscopy Facility of the Center for Genome Research
and Biocomputing at Oregon State University.
Author contributions: JRW, PRB, NIL, EML and JSB treated the mice.
ET, PB and LB performed the immunohistology. JRW, BRR, EJM, CSB
and TWR conducted the mass spectrometric assays. JRW, PRB, NIL, PJC,
CP, MS, MCF, AGE, LB and JSB contributed to the design of the experi-
ments and to the writing of the manuscript, and also conducted
supporting experiments not shown.
Competing interests: PJC and BRR are employees of TheUniversity of
Melbourne. Collaborative Medicinal Development LLC has licensed in-
tellectual property on this subject from The University of Melbourne.
No other conﬂicts are listed.
References
Andersen, P.M., et al., 2003. Sixteen novel mutations in the Cu/Zn superoxide dismutase
gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes.
Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4 (2), 62–73.
Banci, L., et al., 2010. Afﬁnity gradients drive copper to cellular destinations. Nature 465
(7298), 645–648.
Bosco, D.A., et al., 2010. Wild-type and mutant SOD1 share an aberrant conformation and
a common pathogenic pathway in ALS. Nat. Neurosci. 13 (11), 1396–1403.
Brown, N.M., Torres, A.S., Doan, P.E., O'Halloran, T.V., 2004. Oxygen and the copper chap-
erone CCS regulate posttranslational activation of Cu, Zn superoxide dismutase. Proc.
Natl. Acad. Sci. U. S. A. 101 (15), 5518–5523.
Cassina, P., et al., 2002. Peroxynitrite triggers a phenotypic transformation in spinal cord
astrocytes that induces motor neuron apoptosis. J. Neurosci. Res. 67 (1), 21–29.
Dearling, J.L., Packard, A.B., 2010. Some thoughts on themechanism of cellular trapping of
Cu(II)-ATSM. Nucl. Med. Biol. 37 (3), 237–243.
Dearling, J.L., Lewis, J.S., Mullen, G.E., Welch, M.J., Blower, P.J., 2002. Copper
bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure–activity re-
lationships. J. Biol. Inorg. Chem. 7 (3), 249–259.
Deng, H.X., et al., 2006. Conversion to the amyotrophic lateral sclerosis phenotype is asso-
ciated with intermolecular linked insoluble aggregates of SOD1 in mitochondria.
Proc. Natl. Acad. Sci. U. S. A. 103 (18), 7142–7147.
Donnelly, P.S., et al., 2012. An impaired mitochondrial electron transport chain increases
retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)
copperII. Proc. Natl. Acad. Sci. U. S. A. 109 (1), 47–52.
Estevez, A.G., et al., 1999. Induction of nitric oxide-dependent apoptosis in motor neurons
by zinc-deﬁcient superoxide dismutase. Science 286 (5449), 2498–2500.
Franco, M.C., et al., 2013. Nitration of Hsp90 induces cell death. Proc. Natl. Acad. Sci. U. S. A.
110, E1102–E1111.
Guareschi, S., et al., 2012. An over-oxidized form of superoxide dismutase found in spo-
radic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism
with mutant SOD1. Proc. Natl. Acad. Sci. U. S. A. 109 (13), 5074–5079.
Gurney, M.E., et al., 1994. Motor neuron degeneration in mice that express a human Cu,
Zn superoxide dismutase mutation. Science 264, 1772–1775.
Hodgkinson, V.L., et al., 2015. X-linked spinal muscular atrophy in mice caused by auton-
omous loss of ATP7A in the motor neuron. J. Pathol. 236 (2), 241–250.
Hung, L.W., et al., 2012. The hypoxia imaging agent CuII(atsm) is neuroprotective and im-
proves motor and cognitive functions in multiple animal models of Parkinson's dis-
ease. J. Exp. Med. 209 (4), 837–854.
Igoudjil, A., et al., 2011. In vivo pathogenic role of mutant SOD1 localized in themitochon-
drial intermembrane space. J. Neurosci. 31 (44), 15826–15837.
Ikawa, M., et al., 2015. Increased oxidative stress is related to disease severity in the ALS
motor cortex: A PET study. Neurology 84 (20), 2033–2039.
Jaarsma, D., et al., 2001. CuZn superoxide dismutase (SOD1) accumulates in vacuolated
mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked
SOD1 mutations. Acta Neuropathol. (Berl) 102 (4), 293–305.
Jonsson, P.A., et al., 2006. Disulphide-reduced superoxide dismutase-1 in CNS of transgen-
ic amyotrophic lateral sclerosis models. Brain 129 (Pt 2), 451–464.
Kayatekin, C., Zitzewitz, J.A., Matthews, C.R., 2008. Zinc bindingmodulates the entire fold-
ing free energy surface of human Cu, Zn superoxide dismutase. J. Mol. Biol. 384 (2),
540–555.
Kennerson, M.L., et al., 2010. Missense mutations in the copper transporter gene ATP7A
cause X-linked distal hereditary motor neuropathy. Am. J. Hum. Genet. 86 (3),
343–352.
Kong, J., Xu, Z., 1998. Massive mitochondrial degeneration in motor neurons triggers the
onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci.
18 (9), 3241–3250.
Lamb, A.L., Torres, A.S., O'Halloran, T.V., Rosenzweig, A.C., 2000. Heterodimer formation
between superoxide dismutase and its copper chaperone. Biochemistry 39 (48),
14720–14727.Leitner, M., Menzies, S., Lutz, C., 2009. Working With ALS Mice, Guidelines for Preclinical
Testing and Colony Management. The Jackson Laboratory (Appendix A).
Lelie, H.L., et al., 2011. Copper and zinc metallation status of copper–zinc superoxide dis-
mutase from amyotrophic lateral sclerosis transgenic mice. J. Biol. Chem. 286 (4),
2795–2806.
Levenson, C.W., Janghorbani, M., 1994. Long-termmeasurement of organ copper turnover
in rats by continuous feeding of a stable isotope. Anal. Biochem. 221 (2), 243–249.
Manfredi, G., Xu, Z., 2005. Mitochondrial dysfunction and its role in motor neuron degen-
eration in ALS. Mitochondrion 5 (2), 77–87.
Mattiazzi, M., et al., 2002. Mutated human SOD1 causes dysfunction of oxidative phos-
phorylation inmitochondria of transgenic mice. J. Biol. Chem. 277 (33), 29626–29633.
McAllum, E.J., et al., 2013. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse
model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal
Dement. 14, 586–590.
Moore, S.D., Chen, M.M., Cox, D.W., 2000. Cloning andmapping of murine superoxide dis-
mutase copper chaperone (Ccsd) and mapping of the human ortholog. Cytogenet.
Cell Genet. 88 (1–2), 35–37.
Parker, S.J., et al., 2012. Inhibition of TDP-43 accumulation by bis(thiosemicarbazonato)-
copper complexes. PLoS One 7 (8), e42277.
Penland, J.G., Prohaska, J.R., 2004. Abnormal motor function persists following recovery
from perinatal copper deﬁciency in rats. J. Nutr. 134 (8), 1984–1988.
Prohaska, J.R., 1991. Changes in Cu, Zn-superoxide dismutase, cytochrome c oxidase, glu-
tathione peroxidase and glutathione transferase activities in copper-deﬁcient mice
and rats. J. Nutr. 121 (3), 355–363.
Prohaska, J.R., 2014. Impact of copper deﬁciency in humans. Ann. N. Y. Acad. Sci. 1314,
1–5.
Prohaska, J.R., Brokate, B., 2002. The timing of perinatal copper deﬁciency in mice inﬂu-
ences offspring survival. J. Nutr. 132 (10), 3142–3145.
Rakhit, R., et al., 2002. Oxidation-induced misfolding and aggregation of superoxide dis-
mutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem. 277
(49), 47551–47556.
Rhoads, T.W., et al., 2011. Measuring copper and zinc superoxide dismutase from spinal
cord tissue using electrospray mass spectrometry. Anal. Biochem. 415 (1), 52–58.
Rhoads, T.W., et al., 2013. Using theoretical protein isotopic distributions to parse small-
mass-difference post-translational modiﬁcations via mass spectrometry. J. Am. Soc.
Mass Spectrom. 24 (1), 115–124.
Roberts, B.R., et al., 2014. Oral treatment with CuII(atsm) increases mutant SOD1 in vivo
but protects motor neurons and improves the phenotype of a transgenic mouse
model of amyotrophic lateral sclerosis. J. Neurosci. 34 (23), 8021–8031.
Rothstein, J.D., et al., 1999. The copper chaperone CCS is abundant in neurons and astro-
cytes in human and rodent brain. J. Neurochem. 72 (1), 422–429.
Saxena, S., Cabuy, E., Caroni, P., 2009. A role for motoneuron subtype-selective ER stress in
disease manifestations of FALS mice. Nat. Neurosci. 12 (5), 627–636.
Scott, S., et al., 2008. Design, power, and interpretation of studies in the standard murine
model of ALS. Amyotroph. Lateral Scler. 9 (1), 4–15.
Son, M., Elliott, J.L., 2014. Mitochondrial defects in transgenic mice expressing Cu, Zn su-
peroxide dismutase mutations: the role of copper chaperone for SOD1. J. Neurol. Sci.
336 (1–2), 1–7.
Son, M., et al., 2007. Overexpression of CCS in G93A-SOD1 mice leads to accelerated neu-
rological deﬁcits with severe mitochondrial pathology. Proc. Natl. Acad. Sci. U. S. A.
104 (14), 6072–6077.
Son, M., et al., 2008. Isolated cytochrome c oxidase deﬁciency in G93A SOD1mice overex-
pressing CCS protein. J. Biol. Chem. 283 (18), 12267–12275.
Soon, C.P., et al., 2011. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)
(CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs
survival in amyotrophic lateral sclerosis mouse model. J. Biol. Chem. 286 (51),
44035–44044.
Tokuda, E., et al., 2007. Metallothionein proteins expression, copper and zinc concentra-
tions, and lipid peroxidation level in a rodent model for amyotrophic lateral sclerosis.
Toxicology 229 (1–2), 33–41.
Tokuda, E., Okawa, E., Watanabe, S., Ono, S., Marklund, S.L., 2013. Dysregulation of intra-
cellular copper homeostasis is common to transgenic mice expressing humanmutant
superoxide dismutase-1 s regardless of their copper-binding abilities. Neurobiol. Dis.
54, 308–319.
Trumbull, K.A., Beckman, J.S., 2009. A role for copper in the toxicity of zinc-deﬁcient su-
peroxide dismutase to motor neurons in amyotrophic lateral sclerosis. Antioxid.
Redox Signal. 11 (7), 1627–1639.
Trumbull, K.A., et al., 2012. Diapocynin and apocynin administration fails to signiﬁcantly
extend survival in G93A SOD1 ALS mice. Neurobiol. Dis. 45 (1), 137–144.
Turner, B.J., Talbot, K., 2008. Transgenics, toxicity and therapeutics in rodent models of
mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85 (1), 94–134.
Vinsant, S., et al., 2013a. Characterization of early pathogenesis in the SOD1(G93A)mouse
model of ALS: part II, results and discussion. Brain Behav. 3 (4), 431–457.
Vinsant, S., et al., 2013b. Characterization of early pathogenesis in the SOD1(G93A)mouse
model of ALS: part I, background and methods. Brain Behav. 3 (4), 335–350.
